Skip to main content

High Comorbidity Rates with Inclusion Body Myositis

Sep 21, 2021 3:59 pm

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in IBM patients.

Using data from the Rochester Epidemiology Project patients with IBM were compared with other IIM, and age/sex-matched population-controls to examine comorbidities and survival. 

The analysis included 50 IBM patients, 65 IIM-controls, and 294 controls.

The most common feature in IBM was dysphagia (64%). Although IBM had a high frequency of neuropathies, there was no increase in the frequency of neurodegenerative disorders (dementia/Parkinsonism) or solid cancers between groups. Oddly, rheumatoid arthritis was the most common rheumatic disease in all groups.

Frequent findings in IBM patients were peripheral neuropathy (35%), Sjögren’s syndrome (6%), and 10% had a hematologic malignancy; uniquely T-cell large granular lymphocytic leukemia was seen only in IBM patients.  Thus IBM patients were 2.7-times more likely to have peripheral neuropathy, 6.2-times more likely to have Sjögren’s syndrome, and 3.9-times more likely to have a hematologic malignancy compared with population-controls.

Overall, mortality was increased in the IBM group, with a lower 10-year survival (36% IBM) when compared to IIM (67%) and population-controls (59%).  The most common cause of death in IBM was respiratory failure or pneumonia (44%).

Close monitoring of IBM-related comorbidities nd complications is warranted based on these data.

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.